The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy-Reference-Cited by-同舟云学术

The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy

Published:2018-08-29 Issue:3 Volume:56 Page:182-192
ISSN:2501-062X
Container-title:Romanian Journal of Internal Medicine
language:en
Short-container-title:

Author:

Voiosu Andrei Mihai¹,Bălănescu Paul²³,Daha Ioana²⁴,Smarandache Bianca¹,Rădoi Aurelia²,Mateescu Radu Bogdan¹²,Băicuş Cristian Răsvan²³⁵,Voiosu Theodor Alexandru¹²

Affiliation:

1. Gastroenterology Department, “Colentina” Clinical Hospital , Bucharest , Romania

2. UMF “Carol Davila” , Bucharest , Romania

3. CDPC Clinial Immunology Laboratory , “Colentina” Clinical Hospital , Bucharest , Romania

4. Cardiology Department, “Colentina” Clinical Hospital , Bucharest , Romania

5. Internal Medicine Department, “Colentina” Clinical Hospital , Bucharest , Romania

Abstract

Abstract Background. We aimed to determine the relationship between endocan and cirrhotic cardiomyopathy. Materials and methods. Patients with liver cirrhosis and no heart disease were included in a prospective observational study with liver disease decompensation and death as primary outcomes. Results. 83 cirrhotic patients were included and 32 had cirrhotic cardiomyopathy. Endocan levels were significantly lower in patients with cirrhotic cardiomyopathy (5.6 vs. 7 ng/mL, p = 0.034). Endocan correlated with severity of cirrhosis, time to decompensation or death from liver disease (OR 4.5 95% CI 1.06-31.1). Conclusion. Endocan is a promising biomarker of severity of cirrhosis and may help in the diagnosis of cardiac dysfunction in this population.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/rjim-2018-0007

Reference30 articles.

1. 1. SEO K, KITAZAWA T, YOSHINO Y, et al. Characteristics of serum endocan levels in infection. PLoS One. 2015; 10(4):e0123358.10.1371/journal.pone.0123358

2. 2. COX LA, VAN EIJK LT, RAMAKERS BP, et al. Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015; 43(4):322-326.10.1097/SHK.0000000000000320

3. 3. SCHERPEREEL A, DEPONTIEU F, GRIGORIU B, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med.2006; 34(2):532-537.10.1097/01.CCM.0000198525.82124.74

4. 4. PALUD A, PARMENTIER-DECRUCQ E, PASTRE J, et al. Evaluation of endothelial biomarkers as predictors of organ failures in septic shock patients. Cytokine. 2015; 73(2):213-218.10.1016/j.cyto.2015.02.013

5. 5. YANG J, YANG Q, YU S, et al. Endocan: A new marker for cancer and a target for cancer therapy. Biomed Rep. 2015; 3(3):279-283.10.3892/br.2015.438

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocan: A Key Player of Cardiovascular Disease;Frontiers in Cardiovascular Medicine;2022-01-05

2. Endothelial and microvascular function in liver cirrhosis: an old concept that needs re-evaluation?;Annals of Gastroenterology;2022

3. Cirrhotic Cardiomyopathy;Gastroenterology Insights;2021-02-25

4. Cirrhotic Cardiomyopathy—A Veiled Threat;Cardiology in Review;2020-11-20

5. Physiopathological and diagnostic aspects of cirrhotic cardiomyopathy;Archivos de cardiolog�a de M�xico (English ed. Internet);2020-09-08